期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 268, 期 1-2, 页码 95-98出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2014.01.008
关键词
Th17; Interleukin-17; Regulatory T cells; Multiple sclerosis; Fingolimod; Treatment
资金
- Grants-in-Aid for Scientific Research [24790870, 22229008] Funding Source: KAKEN
Fingolimod has demonstrated efficacy in patients with multiple sclerosis (MS), and patients become gradually lymphopenic after a few days of treatment, with selective reductions in CD4+ subsets. We observed an increase in the frequencies of circulating regulatory T cells after fingolimod administration. However, we also found that half of patients had increased proportion of circulating Th17 cells in CD4+ T cells after treatment (including a patient with MS relapses), whereas the others showed lower frequencies of Th17 cells, indicating some variability among patients. Further studies may confirm if slower reduction of circulating Th17 cells following fingolimod initiation predisposes to relapses. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据